CommercialCoverageLow impact
08.00.70e, Enzyme Replacement Therapy for Mucopolysaccharidosis (e.g., Aldurazyme®, Elaprase®, Vimizim®, Naglazyme®, Mepsevii™, etc.)
Independence Blue Cross·Endocrinology, Pediatrics, Oncology·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
This is a reissue of the Enzyme Replacement Therapy policy for Mucopolysaccharidosis (MPS) covering drugs like Aldurazyme, Elaprase, Vimizim, Naglazyme, and Mepsevii. The policy was reposted with an effective date of April 1, 2026, indicating updated coverage or billing requirements for these specialized enzyme replacement therapies.
Action Required
By April 1, 2026: Review updated policy requirements for Enzyme Replacement Therapy medications (Aldurazyme, Elaprase, Vimizim, Naglazyme, Mepsevii) for MPS patients. Billing team should access the full policy at the provided URL to understand any changes to prior authorization, documentation, or billing requirements for these specialty medications.